Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, has announced the appointment of Rebecca Simmons as Chief Operating Officer.
Rebecca will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives, as Qureight drives increased adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for lung and heart diseases.
She will play an instrumental role in driving operational excellence and supporting Qureight’s scientific and technical functions.
With over 20 years of operational leadership experience, Rebecca was previously COO at quantum computing company Riverlane, where she successfully built and scaled the company’s operations to support rapid growth from ten to 100 employees over five years.
Muhunthan Thillai MD, co-founder and CEO, Qureight, commented: “Rebecca’s experience, expertise and people-centric leadership approach will be instrumental in supporting the team as we scale the company, accelerating our mission to advance the understanding of lung and heart disease.”
Rebecca added: “Qureight’s pioneering AI-powered CT imaging biomarkers and data management platform is enabling real insights to be drawn from complex and diverse health data to ultimately deliver real impact for patients.”
